This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.

开始日期2025-03-27

申办/合作机构

Vanderbilt University Medical Center

NCT04756232

/ Completed早期临床1期IIT

Cholinergic Mechanisms of Attention in Aging

开始日期2022-04-21

申办/合作机构

Vanderbilt University Medical Center

NCT03914677

/ Unknown status临床4期IIT

Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis

This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

开始日期2019-06-13

申办/合作机构

Wayne State University (Michigan)

100 项与盐酸美加明相关的临床结果

登录后查看更多信息

100 项与盐酸美加明相关的转化医学

登录后查看更多信息

100 项与盐酸美加明相关的专利（医药）

登录后查看更多信息

3,356

项与盐酸美加明相关的文献（医药）

2025-08-01·NEUROPHARMACOLOGY

Chronic nicotine enhances object recognition memory via inducing long-term potentiation in the medial prefrontal cortex in mice

Article

作者: Nishikawa, Keisuke ; Waki, Fuka ; Nishitani, Naoya ; Kaneda, Katsuyuki ; Kawasaki, Ibuki ; Deyama, Satoshi ; Izumi, Shoma

Chronic nicotine administration enhances cognitive functions, including learning and memory, and ameliorates cognitive impairments observed in psychological and neurodegenerative disorders. However, the detailed mechanisms underlying these effects are not fully understood. In this study, we used a novel object recognition (NOR) test and in vitro slice electrophysiology in mice to investigate the involvement of the medial prefrontal cortex (mPFC), a brain region connected to the hippocampus, and the synaptic plasticity within this region in chronic nicotine-induced object recognition memory enhancement. The NOR test revealed that chronic nicotine administration for five consecutive days significantly enhanced object recognition memory in male and female mice. This effect was blocked by intra-mPFC infusion of mecamylamine (Mec), a non-selective nicotinic acetylcholine receptor (nAChR) antagonist. In parallel with these findings, whole-cell recordings demonstrated that chronic nicotine administration significantly increased the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/N-methyl-d-aspartate (NMDA) ratio in mPFC layer V pyramidal neurons in male but not female mice. This plastic change was suppressed by systemic injection of Mec or methyllycaconitine, an α7 nAChR antagonist. Furthermore, optogenetic erasure of long-term potentiation (LTP) through chromophore-assisted light inactivation of cofilin, a protein essential for stabilizing spine expansion, suppressed chronic nicotine-induced enhancement of recognition memory. These findings suggest that chronic nicotine administration induces LTP in mPFC pyramidal neurons, likely enhancing object recognition memory.

2025-08-01·MOLECULAR NEUROBIOLOGY

Nicotine Attenuates Molecular Signalings in the BTBR T+ Itpr3tf/J Mouse Model of Autism

Article

作者: Aljasham, Alanoud T ; Alasmari, Fawaz ; Mahmood, Hafiz M ; Alasmari, Abdullah F ; AlDhalaan, Hesham M ; Khan, Mohammad R ; AlSharari, Shakir D ; Ahmad, Sheikh F ; Alshammari, Musaad A ; Damaj, Imad M

Accumulating evidence indicates that nicotinic receptor subtypes are altered in the brains of autistic individuals, and nicotinic acetylcholine receptors (nAChRs) play essential roles in autistic profiles in BTBR T⁺ Itpr3^tf/J mice. This study aimed to elucidate the roles of nicotine on systemic inflammatory cytokine levels and expression patterns of nicotinic receptor subtypes in the prefrontal cortex in BTBR T⁺ Itpr3^tf/J mice. This research project characterized the effect of chronic treatment with nicotine at a dose (100 mcg/ml; po) administrated orally in drinking water over a period of fourteen days in BTBR T⁺ Itpr3^tf/J mice, while C57BL/6 J mice were served as the controls. Following the nicotine treatment, the levels of tumor necrosis factor (TNF)-α, interferon (IFN)-γ interleukin (IL)-1β, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were assessed in the serum; the levels of pro-inflammatory cytokines [interleukin (IL)-17 and interferon (IFN)-γ], on CD4⁺ and CD8⁺ T cells were evaluated in the blood. Moreover, the expression of α7, α4, and β2-nAChRs in the prefrontal cortex in BTBR T⁺ Itpr3^tf/J mice was examined. Biochemical analysis showed that nicotine had significantly decreased the concentration of inflammatory cytokines, including TNF-α, IFN-γ, IL-1β, and GM-CSF in the serum, and reduced the expression levels of intracellular pro-inflammatory cytokines (IL-17 & IFN-γ) on CD4⁺ and CD8⁺ T cells in the blood while mecamylamine reversed the effect of IL-17⁺ CD4⁺ T cells. Nicotine administration up-regulated the expressions of α7, α4, and β2 nAChRs in the prefrontal cortex in BTBR T⁺ Itpr3^tf/J mice. The current results indicate that nAChRs play a significant role, at least in part, in ASD and might serve as a crucial target for therapeutic interventions in ASD.

2025-03-01·TRANSPLANT IMMUNOLOGY

Determining the best premedication regimen to prevent rabbit anti-human thymocyte globulin infusion-associated reactions: A retrospective study comparing two hematopoietic stem cell transplant centers

Article

作者: Vachon, Keven ; Leblanc, Marie-Helene ; Paillé, Étienne ; Lemieux, Christopher ; Tardif, Marc-Antoine ; Gallagher, Geneviève ; Cantin, Guy

BACKGROUND:

Thymoglobulin® (ATG), a rabbit anti-human thymocyte globulin, is used in allogeneic hematopoietic stem cell transplantation (HSCT) mainly to prevent the development of graft-versus-host disease (GVHD). Three doses (ATG1, ATG2, and ATG3) are administered on separate days, apart from the graft day. Since infusion-associated reactions (IAR) are frequent, patients were treated with acetaminophen, antihistamine, and corticosteroids (CS) as premedication (PR); however, the best PR regimen remains to be defined.

METHODS:

The study compared the incidence and severity of IAR related to ATG according to the different PR therapy. This descriptive retrospective cohort study included patients receiving ATG in two HSCT transplant centers (Hospitals A and B). The data cut-off was in March 2020, but the period of interest was different between the two hospitals to balance the two groups. Four PR regimens were compared, one from Hospital A (PR-A) and three from Hospital B (PR-B1, B2, and B3), which have changed twice in the last decade. Along with PR therapy, the indication and method of administration of ATG also differed between hospitals.

RESULTS:

A total of 132 patients were included from May 2011 to March 2020. Groups PR-A, B1, B2, and B3 had, respectively, 61, 22, 26, and 23 patients. Of them, 115 (87 %) had at least one IAR, and 86 (65 %) had at least one severe IAR during any ATG infusions. ATG3 had the lowest incidence of IAR (39 %), and it seemed better tolerated when given after graft infusion than before (32 % vs. 46 %, respectively; p = 0.11). Almost three-quarters of patients had at least one IAR that occurred after the end of an ATG infusion, but there was less IAR with PR-B3 protocol where acetaminophen and diphenhydramine were regularly administered beyond ATG infusion. Hospital A used a progressive rate of infusion, but early IAR was seen compared to Hospital B (p = 0.03), where a fixed rate was used. No direct association was found between the CS dose received and IAR incidence (p = 0.21) or severity (p = 0.61). However, there was a recurrent signal for less severe IAR in the PR-B3 group compared to its predecessors, B1 and B2 groups (p = 0.12), and the key difference was an increased CS dose. The mean total CS therapy received was nearly double at Hospital A compared with Hospital B (1182 vs. 692 mg prednisone equivalent; p < 0.01). Fungal infection rate was higher in Hospital A compared to Hospital B (33 % vs. 13 %; p < 0.01). The infection rate correlated with a higher dose of CS received on days of ATG therapy (p < 0.01).

CONCLUSION:

ATG3 given the day after HSCT appears to play a key role in reducing the incidence and severity of IAR. Infusion over six hours at a fixed rate was safe. Frequent, regular, and extended doses of acetaminophen and antihistamines beyond ATG infusion appear useful. Increasing CS doses led to IAR reduction, but this correlated with an increased infection rate.

项与盐酸美加明相关的新闻（医药）

2025-06-23

·GlobeNewswire-Health Care

Optime Care Partners with Tilde Sciences as Exclusive Specialty Pharmacy Provider for Vecamyl

ST. LOUIS, June 23, 2025 (GLOBE NEWSWIRE) -- Optime Care, AscellaHealth’s Specialty Pharmacy, is pleased to announce an expanded partnership with Tilde Sciences LLC (“Tilde”), effective June 23, 2025. Under this arrangement, Optime Care will serve as the exclusive specialty pharmacy provider for dispensing the newly FDA-approved and relaunched Vecamyl (mecamylamine) 2.5 mg tablets to patients. Tilde, a pharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, selected Optime Care for its proven track record in program continuity, prior experience with Vecamyl® and Daraprim® and expertise in managing small, specialized patient populations. “Our continued and expanded relationship with Tilde demonstrates their confidence in Optime Care’s ability to meet the needs of specialty patient populations through highly-personalized programs, tailored patient communications and educational support throughout the treatment journey,” says Bill Bertetto, general manager, Optime Care. “Tilde values the expertise of our dedicated Patient Care Teams who have a deep understanding of complex disease states and provide guidance every step of the way. These specialists help enhance patient access to essential therapies, streamline care coordination and ensure financial assistance is available to those in need.” Leveraging innovative, proprietary technology platforms and patient engagement tools, Optime Care’s expert teams, including specially trained Patient Care Coordinators, deliver end-to-end solutions that drive improved individual outcomes and exceptional compliance rates. Akeel Mithani, president of Tilde states, “Optime Care is a trusted partner, reliably ensuring that patients with rare, complex diseases receive their medications on time and wherever needed. Over a year ago, we made a great decision to partner with Optime Care and we continue to rely on their unmatched expertise. Their teams consistently demonstrate a shared commitment to care for vulnerable specialty patients. It has been a gratifying experience working with Optime Care and we look forward to further collaboration to improve the clinical outcomes and quality of life for the patients we serve.” Vecamyl (mecamylamine) had been unavailable for new patients following its acquisition from the previous owner. The Company has since partnered with new supply chain providers to address and resolve the prior supply challenges. Today, the Company is pleased to announce that Vecamyl is now available through Tilde’s comprehensive patient support program, Tilde Total Care. Questions pertaining to access and affordability of Vecamyl (mecamylamine) should be directed to 1-877-794-0008. About Optime CareOptime Care, Inc., AscellaHealth’s Specialty Pharmacy, is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize therapeutic opportunities for the treatment of orphan and rare disorders. The executive team has partnered in the launch and management of over 40 orphan products and programs while consistently implementing the best brand services for the community. Optime Care has dual-accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers. Visit: https://www.optimecare.com/*Optime Care is wholly owned by Innovative Specialty Solutions, LLC, an affiliate of AscellaHealth, LLC. About Tilde Tilde Sciences is a United States based biopharmaceutical company specializing in the development and commercialization of specialty pharmaceuticals tailored for rare diseases with significant unmet needs. For more information visit https://www.tildesciences.com/ About VECAMYL®INDICATION VECAMYL® (mecamylamine HCI tablets USP) 2.5 mg is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. IMPORTANT SAFETY INFORMATION VECAMYL® should not be used in people with mild, moderate high blood pressure that can suddenly fluctuate at different times of the day. You should not use VECAMYL if you have a heart condition that reduces the flow of blood to the heart or had a recent heart attack. Patients with a certain type of abnormal kidney function should use VECAMYL with caution, and those with increased levels of urea in their blood should not use VECAMYL. In general, it is not advised to use VECAMYL if you are receiving antibiotics and sulfonamides. Do not use VECAMYL if you have glaucoma. Do not use VECAMYL if your healthcare provider indicated you have organic pyloric stenosis. You should not use VECAMYL if you previously had a serious allergic reaction to mecamylamine hydrochloride (the medicine in VECAMYL). VECAMYL should be used with caution if you have a disease that reduces blood flow to the heart and brain, such as arteriosclerosis, or have had a recent stroke. It is important before using VECAMYL that the function of your kidneys and heart are evaluated by your healthcare professional. With certain diseases that reduce blood flow to the kidneys, brain, or heart, some people may experience worsening of symptoms due to reduction of blood pressure with VECAMYL therapy. Also, discuss with your healthcare provider if you have bladder or urinary problems as VECAMYL can make it difficult to completely empty one's bladder. VECAMYL may cause dizziness, lightheadedness, or fainting, especially when rising from a sitting or lying position. This effect may be increased by alcoholic beverages, exercise, or during hot weather. Rising slowly may help prevent these effects. Tell your healthcare provider if you experience tremors, jerky involuntary movements, mental aberrations, or convulsions after taking VECAMYL. Immediately tell your healthcare provider if you experience loose bowel movements with stomach bloating and decreased rumbling. Use VECAMYL as directed by your healthcare provider. The information of this website should not take place of talking to your doctor. If you have any questions about your condition or if you would like more information on VECAMYL, talk to your doctor or pharmacist. Only you and your doctor can decide if VECAMYL is right for you. Do not stop using VECAMYL unless told so by your healthcare provider because suddenly stopping the drug may cause high blood pressure to return. A sudden rise in blood pressure may cause stroke or heart failure. However, the effects of VECAMYL may last from hours to days after one stops using the drug. For more information about VECAMYL, including additional side effects, please see the Full Prescribing Information for VECAMYL. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088. You may also report an adverse event by calling (800) 769-8874. This press release was published by a CLEAR® Verified individual. Media: Caroline Chambers CPR Communications cchambers@cpronline.com 201.641.1911 x 21

并购上市批准

2023-12-07

·PRNewswire

Tilde Sciences acquires Daraprim® and Vecamyl® from Vyera Pharmaceuticals

NEWARK, N.J., Dec. 7, 2023 /PRNewswire/ -- Tilde Sciences, a specialty pharmaceutical company, announced today that it has acquired two medicines, Daraprim® and Vecamyl® from Vyera Pharmaceuticals. Tilde Sciences expects a seamless transition from Vyera Pharmaceuticals and uninterrupted access through Optime Care, its specialty pharmacy partner. Tilde has elected to use Optime Care because of the company's commitment to provide patients and their caregivers with dedicated programs and services in support of these important drugs. If you have any questions about Daraprim® or the financial assistance programs available, call1-877-258-2033 and press 3, or visit . Eligible patients who have commercial insurance may pay as little as $0 out-of-pocket for their prescription.1 Questions related to Vecamyl® should be directed to 1-877-794-0008 or visit . About Tilde Tilde Sciences is a United States based biopharmaceutical company specializing in the development and commercialization of specialty pharmaceuticals tailored for rare diseases with significant unmet needs. For more information visit . 1 Financial assistance programs are subject to terms and conditions and patient eligibility requirements. Restrictions, including where prohibited by law, may apply. Offers are subject to change or discontinuation without notice. Financial assistance programs are not insurance nor are they intended to be a substitute for insurance. SOURCE Tilde Sciences LLC

2023-08-01

·PRNewswire

Vyera Pharmaceuticals, LLC and Phoenixus AG Sign Asset Purchase Agreement to Sell Rights to Daraprim and Vecamyl

NEW YORK and BAAR, Switzerland, Aug. 1, 2023 /PRNewswire/ -- Vyera Pharmaceuticals, LLC ("Vyera") and Phoenixus AG ("Phoenixus") today announced that they have entered into an Asset Purchase Agreement related to Daraprim and Vecamyl. The aggregate consideration to be paid for the sale and transfer of the purchased assets and the assignment of the certain contracts, subject to adjustment, shall be $650,000 together with the assumption of post-closing liabilities. The closing of the transaction is subject to satisfaction of certain conditions, including without limitation approval of the United States Bankruptcy Court for the District of Delaware with which Vyera and Phoenixus, together with affiliated parties, have filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code and have elected to proceed under Subchapter V thereunder. The bankruptcy cases are jointly administered under Case No. 23-10605 (JKS). As part of the Subchapter V proceedings, Vyera filed a motion seeking authorization of its proposed bidding procedures under which to conduct its 363 sale. Additional information about this process and the proposed asset sale, as well as other documents relating to Vyera's Subchapter V proceedings, is available through Vyera's claims and noticing agent's website: . DLA Piper LLP is serving as the Vyera's legal counsel. SierraConstellation Partners LLC is serving as Chief Restructuring Officer and financial advisor, and Alvarez and Marsal Securities LLC is serving as investment banker. For more information about the sale process, interested parties should contact Alvarez and Marsal Securities LLC. About Daraprim DARAPRIM is a prescription medication that contains pyrimethamine for the treatment of toxoplasmosis when used with a sulfonamide (e.g., sulfadoxine). Toxoplasmosis is a serious, sometimes fatal infection caused by the Toxoplasma gondii (T. gondii) parasite, one of the most common parasites in the world. About Vecamyl VECAMYL® (mecamylamine HCI) is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. About Vyera Vyera is a United States based biopharmaceutical company committed to developing and commercializing treatments that address serious and rare diseases with high unmet medical needs. Vyera supports programs that offer financial assistance to patients in need and gives discounts to organizations that provide care to underserved populations. Vyera's research and development efforts focus on novel treatment options for toxoplasmosis and other rare or serious health conditions. . About Phoenixus AG Phoenixus AG is a Swiss based global biopharmaceutical enterprise using a virtual pharma and centralized services development model to reduce the risk, costs and timing of product development across its portfolio companies. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve risks, uncertainties, and assumptions that are difficult to predict. Buyer and Vyera and Phoenixus (collectively, the "Companies") intend that such forward-looking statements be subject to the safe harbors created thereby. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companies' forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companies' cash position, (ii) the Companies' ability to raise additional capital to fund its operations, (iii) the Companies' ability to meet its debt obligations, if any, (iv) the Companies' ability to enter into partnership or licensing arrangements with third parties, (v) the Companies' ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companies' ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companies' clinical trials, (viii) the results of the Companies' clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companies' products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companies' control. Except as required by law, neither Company undertakes any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. Media Contact [email protected] SOURCE Vyera Pharmaceuticals

专利侵权

100 项与盐酸美加明相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00611	盐酸美加明	C02BB01	DB00657

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Targacept, Inc.	1956-03-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
II型糖原贮积病	临床2期	-	CoMentis, Inc.	2008-05-01
糖尿病性黄斑水肿	临床2期	美国	CoMentis, Inc.	2007-09-01
湿性年龄相关性黄斑变性	临床2期	巴西	CoMentis, Inc.	2007-03-01
湿性年龄相关性黄斑变性	临床2期	捷克	CoMentis, Inc.	2007-03-01
湿性年龄相关性黄斑变性	临床2期	墨西哥	CoMentis, Inc.	2007-03-01
湿性年龄相关性黄斑变性	临床2期	波兰	CoMentis, Inc.	2007-03-01
湿性年龄相关性黄斑变性	临床2期	俄罗斯	CoMentis, Inc.	2007-03-01
湿性年龄相关性黄斑变性	临床2期	乌克兰	CoMentis, Inc.	2007-03-01
重度抑郁症	临床2期	-	Targacept, Inc.	2005-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01223404 (CTgov)	N/A	认知	21	placebo (Intervention: Placebo)	糧簾遞膚鏇顧鹽淵獵鬱(蓋簾鏇窪選壓艱鹹壓築) = 蓋築糧鬱夢齋廠繭獵選鹽獵顧衊糧壓製鏇齋遞 (鏇顧築簾積顧齋獵構鏇, 齋廠願遞顧選範廠獵築 ~ 簾遞艱醖網鏇鬱衊餘顧) 更多	-	2018-01-25
				nicotine+placebo (Intervention: Nicotine)	糧簾遞膚鏇顧鹽淵獵鬱(蓋簾鏇窪選壓艱鹹壓築) = 鹽鬱醖製網選醖鬱廠窪鹽獵顧衊糧壓製鏇齋遞 (鏇顧築簾積顧齋獵構鏇, 齋簾鹽製齋餘襯繭糧齋 ~ 築積衊齋艱窪蓋簾廠鹽) 更多
NCT00563797 (CTgov)	临床3期	酗酒 \| 抑郁症 \| 重度抑郁症	21	Placebo (Placebo)	繭鏇淵觸網願遞鏇夢淵(鏇糧鑰醖鹽簾餘範構網) = 製窪鏇積願獵夢網襯範窪積夢鹽鬱願築鏇襯顧 (壓夢衊鏇構鹹積觸鏇築, 6.570) 更多	-	2016-04-18
				Mecamylamine (Mecamylamine)	繭鏇淵觸網願遞鏇夢淵(鏇糧鑰醖鹽簾餘範構網) = 艱觸顧獵齋窪構衊淵膚窪積夢鹽鬱願築鏇襯顧 (壓夢衊鏇構鹹積觸鏇築, 6.570) 更多
NCT00773812 (Pubmed \| J Child Adolesc Psychopharmacol)	临床1期	自闭症谱系障碍	20	Placebo	衊壓淵製鹹積鹽網鹽製(範獵構鏇廠襯網衊鏇壓) = constipation 製繭築製繭繭夢選選顧 (獵蓋願淵齋醖壓衊餘糧 )	不佳	2012-06-01
				Mecamylamine
NCT00414206 (CTgov)	临床2期	湿性年龄相关性黄斑变性	343	Mecamylamine (1% Mecamylamine)	淵夢鹽膚築艱鬱襯膚築 = 築鏇鏇構鹹範餘衊壓夢餘衊壓襯廠壓獵膚衊鏇 (獵醖壓鹽醖淵製簾膚壓, 鏇製構齋鏇廠築廠夢網 ~ 網鏇網簾鬱網鏇鏇廠醖) 更多	-	2010-11-23
				Mecamylamine (0.3% Mecamylamine)	淵夢鹽膚築艱鬱襯膚築 = 鏇襯顧鑰蓋餘膚憲鬱鹹餘衊壓襯廠壓獵膚衊鏇 (獵醖壓鹽醖淵製簾膚壓, 願築齋製簾憲鏇餘觸膚 ~ 簾艱觸廠鬱積窪製鬱範) 更多
NCT00536692 (Pubmed \| Am J Ophthalmol)	临床1/2期	糖尿病性黄斑水肿	-	Topical Mecamylamine	鹽憲構網鏇衊蓋窪構膚(膚鏇糧衊構製蓋範衊網) = 構製鬱憲觸壓獵憲醖獵簾鏇願鬱夢鏇憲襯選壓 (夢鏇鹹網餘淵簾築窪顧 )	-	2010-05-01